GLUD1 and colorectal cancer: Recently, the most reported GLUD1 inhibitor is EGCG (epigallocatechin gallate), targeting a group of enzymes that use NADPH as a cofactor [31], is under clinical trial for several tumors, i.e., prostate, breast, and colorectal cancers (https://clinicaltrials.gov/ct2/home) (accessed on 20 December 2021).